Odonate Therapeutics Priced, Nasdaq: ODT

Developing an oral chemotherapy drug for breast cancer.

Industry: Health Care

Latest Trade: $23.35 0.00 (0.0%)

First Day Return: -4.2%

Return from IPO: -2.7%

Industry: Health Care

We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer ("MBC"). We expect to begin enrolling patients in our multinational, multicenter, randomized, Phase 3 study in MBC, known as CONTESSA, in the fourth quarter of 2017 and report top-line results from this study in 2020. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
more less
IPO News for Odonate Therapeutics
more
IPO Data
IPO File Date 11/13/2017
Offer Price $24.00
Price Range $24.00 - $27.00
Offer Shares (mm) 6.3
Deal Size ($mm) $150
IPO Data
IPO Date 12/06/2017
Offer Price $24.00
Price Range $24.00 - $27.00
Offer Shares (mm) 6.3
Deal Size ($mm) $150
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2013
Employees 44
Website www.odonate.com